REGN Regeneron Pharmaceuticals
Intrinsic value$723.41
Price (at call)$784.67
Margin of safety
-7.8%
vs market (rating basis)
+53.7%
Model unavailable; showing baseline valuation.
⚠ LLM error: empty response; using baseline
The story
Value drivers
| Revenue growth (Y1) | 5.6% |
| Terminal growth | 3.5% |
| Forecast horizon | 10y |
| Target operating margin | 33.6% |
| Years to target margin | 5 |
| Sales-to-capital | 0.50 |
| Beta | 0.50 |
| Failure probability | 0.0% |
| Cost of capital (WACC) | 7.2% |
| Terminal WACC | 9.4% |
Valuation bridge
| PV of explicit FCFF | 27.85B |
| PV of terminal value | 45.49B |
| Equity value | 74.48B |
| ÷ shares → per share | $723.41 |
News
neutral +0.10 · 8 articles
- Sanofi Eyes €25B Dupixent Future, Expands M&A Hunt Ahead of Patent Loss
- Can Intellia's Pipeline Progress Create Long-Term Value Amid Rivalry?
- Why This Biotech Stock Just Got a Rare Double Upgrade
- ALVO Stock Jumps On Double Upgrade — Why Barclays Sees A 59% Upside
- Will Fianlimab-Libtayo Trial Misstatement Lawsuits Change Regeneron Pharmaceuticals' (REGN) Pipeline-Driven Narrative?
- Novo Nordisk vs. Regeneron Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
- Regeneron Pharmaceuticals (REGN) Could Be 5% Undervalued Following Trial Lawsuit News
- Regeneron Highlights Dupixent Growth, Cemdisiran Catalysts and EYLEA HD Momentum
Projected free cash flow to the firm
| Yr | Revenue | Growth | Margin | NOPAT | Reinvest | FCFF | PV |
|---|---|---|---|---|---|---|---|
| 1 | 16.41B | 5.6% | 33.6% | 4.75B | 1.75B | 3.00B | 2.80B |
| 2 | 17.29B | 5.4% | 33.6% | 5.01B | 1.77B | 3.24B | 2.82B |
| 3 | 18.18B | 5.1% | 33.6% | 5.26B | 1.78B | 3.48B | 2.83B |
| 4 | 19.08B | 4.9% | 33.6% | 5.52B | 1.79B | 3.73B | 2.83B |
| 5 | 19.97B | 4.7% | 33.6% | 5.78B | 1.78B | 4.00B | 2.82B |
| 6 | 20.85B | 4.4% | 33.6% | 6.04B | 1.77B | 4.26B | 2.81B |
| 7 | 21.73B | 4.2% | 33.6% | 6.29B | 1.75B | 4.54B | 2.79B |
| 8 | 22.59B | 4.0% | 33.6% | 6.54B | 1.73B | 4.81B | 2.76B |
| 9 | 23.44B | 3.7% | 33.6% | 6.78B | 1.69B | 5.10B | 2.72B |
| 10 | 24.26B | 3.5% | 33.6% | 7.02B | 1.64B | 5.38B | 2.68B |